© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
February 15, 2022
An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
Recommendations regarding best approaches to using novel therapies to treat multiple myeloma based on current drug approvals as well as new therapies in the pipeline.
Treatment options available for an elderly man with multiple myeloma upon first relapse.
February 08, 2022
What needs to be investigated further before adopting MRD assessments for multiple myeloma into routine clinical practice.
Considerations for selecting between a conventional front-line triplet regimen to manage a patient with high-risk multiple myeloma who is ineligible for transplant vs a new quadruplet regimen, as demonstrated in recent clinical trial data.
February 01, 2022
Various considerations affect choice of first-line therapy for a patient with newly diagnosed multiple myeloma who is ineligible for transplant.
An overview of treatment regimens available for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation.
January 25, 2022
The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.